Navigation Links
Genta Submits NDA Amendment to FDA for Genasense as Treatment of Chronic Lymphocytic Leukemia
Date:6/6/2008

rrently have CLL. The disease arises in lymphocytes, a type of white blood cell that normally produces antibodies and serves important immune functions. Patients with CLL typically develop symptoms that may progress over a period of years, ultimately producing a generalized depression of immunity, marked increases in the size of spleen, liver and lymph nodes, and impaired production of other normal blood cells. Eventually, these problems may cause life-threatening complications, such as overwhelming infections and fatal bleeding. More information about CLL can be accessed at the website for the Lymphoma Research Foundation at: http://www.lymphoma.org.

About Genasense

Genasense inhibits production of Bcl-2, a protein made by cancer cells that is thought to block chemotherapy-induced apoptosis (programmed cell death). By reducing the amount of Bcl-2 in cancer cells, Genasense may enhance the effectiveness of current anticancer treatment. Genta is pursuing a broad clinical development program with Genasense evaluating its potential to treat various forms of cancer.

About Genta

Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. Two major programs anchor the Company's research platform: DNA/RNA-based Medicines and Small Molecules. Genasense(R) (oblimersen sodium) Injection is the Company's lead compound from its DNA/RNA Medicines program. Genta is currently recruiting patients to the AGENDA Trial, a global Phase 3 trial of Genasense in patients with advanced melanoma. The leading drug in Genta's Small Molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer-related hypercalcemia that is resistant to hydration. The Company has developed G4544, an oral formulatio
'/>"/>

SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Genta Announces Presentation of New Clinical and Preclinical Data on Genasense(R) at AACR-NCI-EORTC Targets Conference
2. Syngenta Licenses Chromatin Gene Stacking Technology
3. Genta Completes Appeal of FDA Decision for Genasense(R) in CLL
4. Genta Receives Notice of Non-Compliance with Listing Requirement for NASDAQ Global Market
5. Syngenta and The Royal Society of Chemistry Launch African Science Initiative
6. Genta Incorporated to Present at Lazard Capital Markets 4th Annual Healthcare Conference
7. Genta Receives NASDAQ Non-Compliance Notice
8. Genta Receives Notice of Non-Compliance With NASDAQ Rule
9. Genta Incorporated to Present at the BIO CEO & Investor Conference
10. Genta Announces Common Stock Offering of Approximately $3.1 Million
11. Genta Announces Senior Management Changes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... Continental Clinical Solutions, LLC (Continental) focuses ... at its mid-Atlantic late-phase research facility, located in ... the idea of closing patient disparities in mind. ... advances," said Continental's CEO, Saleh Stevens . ... cell line of Henrietta Lacks, dubious ethical practices ...
(Date:11/23/2014)... November 23, 2014 Apiscent Labs, ... of fine chemical ingredients to the global pharmaceutical ... of its new website, Apiscent.com. , The Apiscent.com ... Labs, clean design, easy navigation, rotating images and ... Labs stand out. , The company’s ...
(Date:11/22/2014)... 2014 RURO, Inc., a leading ... released Limfinity® version 5.1.4. , RURO’s deployment teams ... than ever in RURO’s 8 year history. Many ... enhancement. Limfinity® version 5.1.4 is the perfect example ... bug fixes! , Limfinity® 5.1.4 release highlights – ...
(Date:11/22/2014)...   , ... zu KLOX    Mariano ... Officer bestellt    KLOX ist bestens ... zugelassenen Behandlungssystems zur Wundheilung zu beginnen    , ... sehr erfreut, die folgenden personellen Veränderungen anzukündigen: ...
Breaking Biology Technology:At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 3RURO Announces Limfinity® version 5.1.4 2KLOX Technologies meldet Neubesetzung von Führungspositionen 2KLOX Technologies meldet Neubesetzung von Führungspositionen 3KLOX Technologies meldet Neubesetzung von Führungspositionen 4KLOX Technologies meldet Neubesetzung von Führungspositionen 5
... against osteoporosis-related fractures, including spine and hip, - Reclast reduced ... to placebo in study published in New England Journal of Medicine, - Unique ... ... - Osteoporotic fractures affect one in two women over 50(1) and are ...
... a biotechnology company developing pharmaceutical products for use ... financing deal. The majority of the funding, $2.3 ... remainder was borrowed from the Madison Development Corporation, ... a private investment firm. The funds raised will ...
... the next strange idea you hear strange: the person ... door. , ,A panel of experienced entrepreneurs speaking ... Milwaukee last Wednesday have dealt with looks and whispers ... in the audience to accept the whispers as a ...
Cached Biology Technology:Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis 2Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis 3Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis 4Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis 5Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis 6Quintessence Secures Financing 2Quintessence Secures Financing 3Lowering the fear factor for entrepreneurs, intra-preneurs 2Lowering the fear factor for entrepreneurs, intra-preneurs 3
(Date:11/4/2014)... Nov. 5, 2014 – University of Utah engineers developed ... help jet fuel produce electricity without needing to ignite ... to power portable electronics, off-grid power and sensors. , ... in the American Chemical Society journal ACS Catalysis ... a chemical reaction between a fuel and an oxygen-rich ...
(Date:11/4/2014)...   3D scanner ... Fuel3D , a developer of 3D scanning solutions, ... $6.4 million (£4 million). This funding builds on the company,s ... and paves the way for the commercial launch of the ... round was led by Chimera Partners and will be used ...
(Date:11/3/2014)... 3, 2014  NeuroSigma ® , Inc. (NeuroSigma), ... company focused on commercialization of its non-invasive ... treatment of neurological and neuropsychiatric disorders, announced today ... issued a Notice of Allowance for Mexican Patent ... by NeuroSigma and the Regents of the University ...
Breaking Biology News(10 mins):Jet-fueled electricity at room temperature 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3
... Education Association (SEA) is preparing to conduct the first-ever research ... debris in the North Atlantic Ocean. The ... 20-year data set previously collected by SEA that reveals a ... in the western North Atlantic Ocean. This trip ...
... from the University of Warwick has discovered taking too much ... your cholesterol by almost 10%. Selenium is a trace ... from foods such as vegetables, meat and seafood. However, when ... selenium, such as through taking selenium supplements, it can have ...
... , This release is available in French ... more than 3 times per week show a worse performance in ... of exposure to mercury show a generalised delay in cognitive, memory ... fish and canned fish and to a lesser extent in white ...
Cached Biology News:SEA to conduct expedition dedicated to measuring plastic marine debris in the North Atlantic Ocean 2Too much selenium can increase your cholesterol 2Consumption of certain fish during pregnancy associated with poorer cognitive performance 2
... cells (BTI-TN-5B1-4) derived from Trichoplusia ni ... to be capable of expressing significantly ... compared to other insect cells. High ... doubling time as adherent cultures- Quick adaptation ...
... assay system offers the following ... for batch-processing systems, Long lasting ... microplates such as 384-well and ... storage conditions ( 2 - ...
... universal lysis buffer, PCR mix, DNA polymerase ... l volume PCR reactions. This system can ... positive rod and coccus bacteria, such as ... Aureus, Streptococcus Agalactiae, and etc. With the ...
... Staining Kit is uniquely formulated to ... minimal protein modification for optimal mass ... associated with traditional silver stains are ... the reagents used do not modify ...
Biology Products: